Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
The company will start its confirmatory bexobrutideg study in June.
A first-in-human trial of PRT12396 starts next month.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
